ADLARITY Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Adlarity, and when can generic versions of Adlarity launch?

Adlarity is a drug marketed by Corium and is included in one NDA. There are nine patents protecting this drug.

This drug has eighty-nine patent family members in eleven countries.

The generic ingredient in ADLARITY is donepezil hydrochloride. There are thirty-two drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adlarity

A generic version of ADLARITY was approved as donepezil hydrochloride by AUROBINDO on May 31^st, 2011.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ADLARITY?
What are the global sales for ADLARITY?
What is Average Wholesale Price for ADLARITY?

Summary for ADLARITY

International Patents:	89
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	160
Patent Applications:	4,015
Drug Prices:	Drug price information for ADLARITY
What excipients (inactive ingredients) are in ADLARITY?	ADLARITY excipients list
DailyMed Link:	ADLARITY at DailyMed

Drug patent expirations by year for ADLARITY

Pharmacology for ADLARITY

Drug Class	Cholinesterase Inhibitor
Mechanism of Action	Cholinesterase Inhibitors

US Patents and Regulatory Information for ADLARITY

ADLARITY is protected by nine US patents and one FDA Regulatory Exclusivity.

Patents protecting ADLARITY

Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

Donepezil transdermal delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Systems and methods for long term transdermal administration
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

Systems comprising a composite backing and methods for long term transdermal administration
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

Methods for treating alzheimer's disease with donepezil transdermal system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

Donepezil transdermal delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

FDA Regulatory Exclusivity protecting ADLARITY

NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-002	Mar 11, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Corium	ADLARITY	donepezil hydrochloride	SYSTEM;TRANSDERMAL	212304-001	Mar 11, 2022		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ADLARITY

See the table below for patents covering ADLARITY around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
South Korea	20220082929	아민 약물의 나트륨 바이카보네이트 제자리 전환 구동된 경피성 전달 (SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG)	⤷ Sign Up
Russian Federation	2018127642	СИСТЕМЫ И СПОСОБЫ ДЛИТЕЛЬНОГО ТРАНСДЕРМАЛЬНОГО ВВЕДЕНИЯ	⤷ Sign Up
South Korea	20230109782	아민 약물의 나트륨 바이카보네이트 제자리 전환 구동된경피성 전달 (SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG)	⤷ Sign Up
European Patent Office	3490541	FORMULATION TRANSDERMIQUE ET PROCÉDÉ D'ADMINISTRATION D'UN MÉDICAMENT DE FORME NEUTRE NON IONISÉ DE FAIBLE SOLUBILITÉ OU INSTABLE PAR CONVERSION SEL DE MÉDICAMENTSUR PLACE (TRANSDERMAL FORMULATION AND DELIVERY METHOD OF LOW SOLUBILITY OR UNSTABLE UNIONIZED NEUTRAL DRUGS BYIN SITU)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for ADLARITY

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0296560	2/1998	Austria	⤷ Sign Up	PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214
0296560	SPC/GB97/023	United Kingdom	⤷ Sign Up	PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description